Prescribing information

 

Support for KISQALI prescribers

These resources are designed to help KISQALI prescribers. You can preview and download these resources, and if you would like to receive more information or copies of any materials, please contact a Novartis representative.

Your Choice is a dedicated support programme designed to facilitate monitoring of KISQALI patients in day-to-day practice.

YOUR CHOICE WITH KISQALI

Your Choice is a dedicated support programme designed to facilitate monitoring of KISQALI patients in day-to-day practice.

Find out more

Download

Therapy management guide

Therapy management guide

This guide provides information for healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.

Download

 

PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR

PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR

This booklet provides information for patients about what to expect from treatment with KISQALI + AI.

Download

PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT

PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT

This booklet provides information for patients about what to expect from treatment with KISQALI + fulvestrant.

Download

 

KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

AI, aromatase inhibitor.

  1. KISQALI (ribociclib). Summary of Product Characteristics.

 

Rate this content: 
No votes yet
UK | June 2021 | 126164
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]